Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JBIO NYSE:NKGN NASDAQ:PLRZ NASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJBIOJade Biosciences$7.36+8.7%$8.68$6.57▼$105.00$6.19M1.03116,071 shs186,077 shsNKGNNKGen Biotech$0.14-17.6%$0.24$0.10▼$0.96$6.29M1.191.65 million shs14,577 shsPLRZPolyrizon$1.10-1.8%$0.97$0.55▼$1,200.00$6.59MN/A10.35 million shs627,609 shsSHPHShuttle Pharmaceuticals$3.32-5.1%$3.85$3.00▼$82.50$1.46M-1.0847,633 shs48,813 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJBIOJade Biosciences0.00%-1.74%-22.61%+735,999,900.00%+735,999,900.00%NKGNNKGen Biotech0.00%0.00%-44.00%-59.98%-84.46%PLRZPolyrizon0.00%0.00%+13.45%-33.33%+109,999,900.00%SHPHShuttle Pharmaceuticals0.00%-2.92%-15.74%-38.52%-93.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJBIOJade Biosciences2.301 of 5 stars3.50.00.00.02.11.70.6NKGNNKGen Biotech0.2226 of 5 stars0.02.00.00.00.62.50.0PLRZPolyrizonN/AN/AN/AN/AN/AN/AN/AN/ASHPHShuttle Pharmaceuticals1.1915 of 5 stars0.05.00.00.02.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJBIOJade Biosciences 3.00Buy$16.00117.39% UpsideNKGNNKGen Biotech 0.00N/AN/AN/APLRZPolyrizon 0.00N/AN/AN/ASHPHShuttle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SHPH, NKGN, JBIO, and PLRZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025JBIOJade BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $18.007/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJBIOJade BiosciencesN/AN/AN/AN/A$239.79 per shareN/ANKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/APLRZPolyrizonN/AN/AN/AN/A$315.05 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$8.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJBIOJade Biosciences-$69.63M-$30.33N/A∞N/AN/A-51.96%-47.65%N/ANKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/APLRZPolyrizon-$1.54MN/A0.00∞N/AN/AN/AN/AN/ASHPHShuttle Pharmaceuticals-$9.15M-$4.15N/A∞N/AN/A-772.76%-347.06%9/2/2025 (Estimated)Latest SHPH, NKGN, JBIO, and PLRZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025JBIOJade Biosciences-$0.43-$0.86-$0.43-$0.86N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJBIOJade BiosciencesN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJBIOJade BiosciencesN/A10.3132.01NKGNNKGen BiotechN/A0.020.02PLRZPolyrizonN/A10.1610.16SHPHShuttle PharmaceuticalsN/A3.072.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJBIOJade BiosciencesN/ANKGNNKGen Biotech76.17%PLRZPolyrizonN/ASHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipJBIOJade Biosciences24.90%NKGNNKGen Biotech10.36%PLRZPolyrizonN/ASHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJBIOJade Biosciences20840,000632,000N/ANKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionablePLRZPolyrizonN/A5.99 millionN/AN/ASHPHShuttle Pharmaceuticals5439,000384,000Not OptionableSHPH, NKGN, JBIO, and PLRZ HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Second Quarter 2025 Corporate UpdateAugust 16 at 3:24 AM | finanznachrichten.deShuttle Pharma Provides Second Quarter 2025 Corporate UpdateAugust 14 at 4:14 PM | globenewswire.comShuttle Pharmaceuticals COO Resigns Amid Leadership ChangesJuly 30, 2025 | tipranks.comShuttle Pharmaceuticals Inc News (SHPH) - Investing.comJuly 2, 2025 | investing.comSHPH - Shuttle Pharmaceuticals Holdings Inc Key Metrics | MorningstarJune 28, 2025 | morningstar.comMShuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market - MorningstarJune 26, 2025 | morningstar.comMSHPH - Shuttle Pharmaceuticals Holdings Inc News | MorningstarJune 26, 2025 | morningstar.comMShuttle Pharmaceuticals Secures $4.25M in Private PlacementJune 26, 2025 | msn.comShuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-MarketJune 24, 2025 | globenewswire.comShuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-MarketJune 20, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings Inc trading halted, news pendingJune 14, 2025 | msn.comShuttle Pharmaceuticals says reverse stock split to become effective June 16June 13, 2025 | finance.yahoo.comShuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern TimeJune 12, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc. Proposes 25-for-1 Reverse Stock Split to Comply with Nasdaq RequirementsJune 12, 2025 | quiverquant.comQShuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance InitiativeJune 12, 2025 | globenewswire.comShuttle Pharma Appoints George Scorsis Chairman of the Board of DirectorsJune 4, 2025 | globenewswire.comShuttle Pharmaceuticals slashes exec salaries by 70% as it fights to preserve cashMay 29, 2025 | bizjournals.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deShuttle Pharma Provides Corporate UpdateMay 15, 2025 | globenewswire.comShuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical TrialMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSHPH, NKGN, JBIO, and PLRZ Company DescriptionsJade Biosciences NASDAQ:JBIO$7.36 +0.59 (+8.71%) As of 08/15/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.NKGen Biotech NYSE:NKGN$0.14 -0.03 (-17.65%) As of 08/15/2025 01:49 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Polyrizon NASDAQ:PLRZ$1.10 -0.02 (-1.79%) As of 08/15/2025 04:00 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.Shuttle Pharmaceuticals NASDAQ:SHPH$3.32 -0.18 (-5.14%) Closing price 08/15/2025 03:59 PM EasternExtended Trading$3.42 +0.10 (+3.04%) As of 08/15/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access